Abstract
Treatment of drug addiction remains an unmet medical need due to the dearth of approved pharmacotherapies. There are no approved treatments for cocaine addiction, whereas the current opioid crisis has revealed the stark reality of the limited options to treat prescription and illicit opioid abuse. Preclinical studies in rodents and nonhuman primates have shown that orphanin FQ/nociceptin (N/OFQ), the endogenous ligand for the nociceptin opioid receptor (NOP) reduces the rewarding effects of several abused substances, including opioids, psychostimulants and alcohol. A few nonpeptide small-molecule NOP agonists have also shown efficacy in attenuating the rewarding effects of various abused drugs. We previously demonstrated that a high affinity small-molecule NOP agonist AT-312 selectively reduced the rewarding effects of ethanol in the conditioned place preference paradigm in mice. In the present study, we examined if AT-312 (3 mg/kg, i.p. or s.c. respectively), would alter the rewarding action of morphine (7.5 mg/kg, s.c.) or cocaine (15 mg/kg, i.p.). The effect of AT-312 on morphine- and cocaine-induced motor stimulation was also assessed on the conditioning days. The role of the NOP receptor in the effects of AT-312 was further confirmed by conducting the place conditioning experiments in NOP knockout mice and compared to their wild-type controls. Our results showed that AT-312 significantly reduced the acquisition of morphine and cocaine CPP in wild-type mice but not in mice lacking NOP receptors. AT-312 also suppressed morphine-induced and completely abolished cocaine-induced motor stimulation in NOP wild-type mice, but not in NOP knockout mice. These results show that small-molecule NOP receptor agonists have promising efficacy for attenuating the rewarding effects of morphine and cocaine, and may have potential as pharmacotherapy for opioid and psychostimulant addiction or for treating polydrug addiction.
Highlights
Addiction pharmacotherapy remains an area severely in need of new approaches and new targets, given that there are no approved therapies for cocaine addiction and the limited suboptimal options available for those addicted to opioids fueling the opioid crises
These results indicate that AT-312 blocked the acquisition of morphine-induced conditioned place preference (CPP) via the nociceptin opioid receptor (NOP) receptor
Previous studies have shown that nonhuman primates have shown that orphanin FQ/nociceptin (N/OFQ) reduces the rewarding action of morphine [17, 35], raising the possibility that nonpeptide NOP agonists may reduce the rewarding effects of opioids
Summary
Addiction pharmacotherapy remains an area severely in need of new approaches and new targets, given that there are no approved therapies for cocaine addiction and the limited suboptimal options available for those addicted to opioids fueling the opioid crises. Most addictive substances cause an increase in dopamine release in the mesolimbic areas of the reward circuitry, albeit through different mechanisms. Even the endogenous opioid peptides, beta-endorphin and enkephalins increase the activity of the mesolimbic dopaminergic neurons and stimulate dopamine release in the NAc [6]. The endogenous opioid system has been shown to be involved in the rewarding actions of other drugs of abuse such as cocaine and alcohol [7,8,9]. Approaches that inhibit the dopaminergic transmission in the mesolimbic circuitry may be useful for reducing rewarding effects of many different addictive drugs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
